Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Aranesp: The heart of the matter

Prolonged anemia can lead to serious heart disease, providing a rationale for using drugs that stimulate red blood cell production to improve cardiovascular outcomes. Yet this hasn't been tested in practice until now. Last week, Amgen Inc. said it had begun a Phase III trial of its Aranesp darbapoetin to study the impact of

Read the full 542 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers